Changing the Course of Cardiovascular Disease.
Cardurion Pharmaceuticals is a clinical-stage biotechnology company pioneering next-generation therapeutics for cardiovascular disease. The company has two active clinical programs: a PDE9 inhibitor (CRD-750) in Phase 2 trials for heart failure, and a CaMKII inhibitor for rare arrhythmias including catecholaminergic polymorphic ventricular tachycardia (CPVT) and broader cardiovascular indications. Founded by physician-scientist Dr. Michael E. Mendelsohn, Cardurion is backed by Bain Capital Life Sciences, headquartered in Burlington, Massachusetts with a research affiliate in Japan.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJul 2024
Oct 2021
Jan 2021
Jan 2020
Jan 2019
Jan 2018
Aug 2017
Jan 2017
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
